MDMA for PTSD granted Expanded Access by FDA, patient treatments begin

MDMA is commonly known as Ecstasy, a party drug. But since the 70s it has been thought that it could help with psychiatric issues. Research of the compound for therapeutic purposes has long been restricted because of regulatory red tape, general fear, and vested interests. Under recent reforms however, what is often called “compassionate use”, some have new hope.

(From New Atlas)

Marking an impressive milestone in the development of MDMA-assisted psychotherapy for PTSD, the U.S. Food and Drug Administration (FDA) has approved the treatment for Expanded Access, allowing certain patients access to the therapy before full market approval is granted. Ten treatment clinics in the United States are reported as ready to commence administration of the therapy, while Phase 3 trials are ongoing and full approval is estimated for 2022.